LENZ · LENZ Therapeutics, Inc.
$4.67
+0.08 (+1.74%)
At close · Aug 25
Market Cap
$146.06M
Shares
31.42M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Evert Schimmelpennink | President and Chief Executive Officer | $7,036,009 |
| Marc Odrich | Chief Medical Officer | $2,436,788 |
| Shawn Olsson | Chief Commercial Officer | $2,387,388 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Evert Schimmelpennink | President and Chief Executive Officer | $6,983,510 |
| Daniel Chevallard | Chief Financial Officer | $3,063,051 |
| Marc Odrich | Chief Medical Officer | $2,039,143 |
| Shawn Olsson | Chief Commercial Officer | $1,958,536 |
| Kimberlee C. Drapkin | Former Interim President and Chief Executive Officer, and Director | $1,097,345 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Evert Schimmelpennink | President and Chief Executive Officer | $2,517,407 |
| Marc Odrich | Chief Medical Officer | $920,163 |
| Kimberlee C. Drapkin | Former Interim President and Chief Executive Officer, and Director | $271,669 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Josh Lehrer | President, Chief Executive Officer and Director | $5,490,535 |
| Alethia Young | Chief Financial Officer | $1,835,489 |
| Philip P. Gutry | Chief Business Officer | $1,382,033 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Josh Lehrer | President, Chief Executive Officer and Director | $7,922,159 |
| Katherine V. Stultz | Former Chief Operating Officer | $2,516,347 |
| Philip P. Gutry | Chief Business Officer | $2,088,030 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Katherine V. Stultz | Former Chief Operating Officer | $750,647 |
| Philip P. Gutry | Chief Business Officer | $706,665 |
| Josh Lehrer | M.D., President and Chief Executive Officer | $455,063 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Zach Scheiner | member of the Company's Board of Directors | Resigned | 2026-07-02 |
| Dan Chevallard | Chief Financial Officer | Appointed | 2024-03-22 |
| Mr. George | Chair of the Board | Appointed | 2024-03-22 |
| Marc Odrich, M.D. | Chief Medical Officer | Appointed | 2024-03-22 |
| Jeff George | Chair of the Board | Appointed | 2024-03-22 |
| Marc Odrich | Chief Medical Officer | Appointed | 2024-03-22 |
| Shawn Olsson | Chief Commercial Officer | Appointed | 2024-03-22 |
| Evert Schimmelpennink | Chief Executive Officer, President, and Secretary | Appointed | 2024-03-22 |
| Daniel Chevallard | Chief Financial Officer | Appointed | 2024-03-22 |
| Kimberlee C. Drapkin | principal executive, financial and accounting officer | Appointed | 2023-08-23 |
| Kimberlee C. Drapkin | principal executive, financial and accounting officer | Appointed | 2023-08-23 |
| Kimberlee C. Drapkin | President and Chief Executive Officer | Appointed | 2023-08-23 |
| Kimberlee C. Drapkin | director | Appointed | 2023-08-02 |
| Alethia Young | Chief Financial Officer | Resigned | 2023-06-23 |
| Philip P. Gutry | principal financial officer and principal accounting officer | Resigned | 2022-03-02 |
| Alethia Young | principal financial officer and principal accounting officer | Appointed | 2022-03-02 |
| Alethia Young | Chief Financial Officer | Appointed | 2022-03-02 |
Key facts
CIK
1815776
CUSIP
52635N103
13F (30d)
127 filings
127 filers
Visit website
Investor relations